Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Acadia Pharmaceuticals (ACAD) Change in Intangibles (2025)

Acadia Pharmaceuticals has reported Change in Intangibles over the past 1 years, most recently at $98.8 million for Q1 2025.

Quarterly results put Change in Intangibles at $98.8 million for Q1 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $98.8 million (changed N/A YoY), and the annual figure for FY2025 was $98.8 million, changed.
Change in Intangibles for Q1 2025 was $98.8 million at Acadia Pharmaceuticals.
Over the last five years, Change in Intangibles for ACAD hit a ceiling of $98.8 million in Q1 2025 and a floor of $98.8 million in Q1 2025.